XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)
Authors:
- Óscar FernándezÓFÓscar Fernández
- Xavier MontalbanXMXavier Montalban
- Adrián ArésAAAdrián Arés
- Eduardo AgüeraEAEduardo Agüera
- Yolanda AladroYAYolanda Aladro
- Ana AlonsoAAAna Alonso
- Rafael ArroyoRARafael Arroyo
- Luis BrievaLBLuis Brieva
- Carmen CallesCCCarmen Calles
- Ana Belén CamineroACAna Belén Caminero
- Tamara Castillo-TriviñoTCTamara Castillo-Triviño
- Lucienne Costa-FrossardLCLucienne Costa-Frossard
Open Access
- 14 August 2026
- journal article
- review article
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (8)
Abstract
The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of the meeting was to summarise the latest developments in the pathogenesis, new diagnostic criteria and biomarkers of MS. This article is the first of a two-part series (I and II) that reviews recent data on cell trafficking into the central nervous system, highlighting the functional heterogeneity of the brain endothelium, the molecular mechanisms regulating leukocyte infiltration and the differential role of macrophages and resident microglia in tissue damage and chronic inflammation. The evidence supporting the role of Epstein-Barr virus as a necessary risk factor in MS is presented, together with the therapeutic and preventive implications from studies of antiviral therapies, cell-based therapies and vaccines. Regarding diagnosis, the new criteria for neuromyelitis optica spectrum disorders are addressed, with particular attention to the molecular heterogeneity of double-seronegative forms, as well as the update of the magnetic resonance imaging (MRI) guidelines following the 2024 revision of the McDonald criteria. Advances in the neuroimaging of chronic active inflammation, quantitative spinal cord imaging and the concept of spinal cord reserve are highlighted. The growing role of artificial intelligence applied to MRI for the early prediction of progression and treatment response is also reviewed. Finally, advances in remyelination mechanisms and in biomarkers are presented, underscoring the value of multimodal and longitudinal approaches for prognostic stratification and treatment monitoring. Overall, the data reviewed reflect a change into a more integrated and predictive understanding of MS, with direct implications for early diagnosis, treatment personalisation and the design of future clinical trials.Keywords
This publication has 28 references indexed in Scilit:
- Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaThe Lancet Neurology, 2025
- 2024 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisThe Lancet Neurology, 2025
- Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-upJournal of Neurology, 2025
- The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life useMultiple Sclerosis and Related Disorders, 2025
- snRNA-seq stratifies multiple sclerosis patients into distinct white matter glial responsesNeuron, 2024
- Fluid biomarkers in multiple sclerosis: from current to future applicationsThe Lancet Regional Health - Europe, 2024
- Optic Nerve Imaging in Multiple Sclerosis and Related DisordersNeuroimaging Clinics Of North America, 2024
- Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosisNature Communications, 2024
- Risk of Multiple Sclerosis in People Living with HIV: An International Cohort StudyAnnals of Neurology, 2023
- Estimating individual treatment effect on disability progression in multiple sclerosis using deep learningNature Communications, 2022